Anti-CD151 antibodies and their use in the treatment of cancer
The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.
1. An isolated antibody that is capable of binding to the CD151 protein and comprises:
i) a light chain comprising CDR-L1, CDR-L2, and CDR-L3, wherein:
CDR-L1 is chosen from SEQ ID No. 43 and SEQ ID No. 85;
CDR-L2 is chosen from SEQ ID No. 44 and SEQ ID No. 86;
CDR-L3 is SEQ ID No. 45; and
ii) a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3, wherein
CDR-H1 is chosen from SEQ ID No. 46 and SEQ ID No. 87;
CDR-H2 is chosen from SEQ ID No. 47 and SEQ ID No. 88;
CDR-H3 is chosen from SEQ ID No. 48 and SEQ ID No. 89;
or a CD151-binding fragment of said antibody.
2. The isolated antibody according to claim 1 , wherein the antibody comprises a light chain comprising SEQ ID No. 49 and a heavy chain comprising SEQ ID No. 50;
or a CD151-binding fragment of said antibody.
3. The isolated antibody according to claim 1 , wherein the antibody comprises a light chain comprising SEQ ID No. 95 and a heavy chain comprising SEQ ID No. 96;
or a CD151-binding fragment of said antibody.
4. The isolated antibody according to claim 1 , wherein the antibody comprises a light chain comprising SEQ ID No. 95 and a heavy chain comprising SEQ ID No. 97;
or a CD151-binding fragment of said antibody.
5. A murine hybridoma deposited at the CNCM (Collection Nationale de Cultures de Microorganismes), Institut Pasteur, Paris (France) on 21 Feb. 2008 under number I-3919.
6. A composition comprising an excipient or a pharmaceutically acceptable carrier, and:
a) an antibody according to one of claims 1 - 4 ;
b) an antibody produced by a hybridoma according to claim 5 ; or
c) a CD151-binding fragment of an antibody as in a) or b).
7. The composition according to claim 6 , further comprising as a combination product for simultaneous, separate, or time-staggered use, an antibody, a cytotoxic/cytostatic agent, a cell toxin, or a radioelement.
8. The composition of claim 6 , wherein the antibody in a) is a chimeric antibody.
9. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to one of claims 1 - 4 , an antibody produced by the hybridoma according to claim 5 , or a combination thereof.
10. The method according to claim 9 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.
11. An antibody secreted by the hybridoma according to claim 5 .
12. The antibody of claim 1 , wherein the antibody is a chimeric antibody.
13. The antibody of claim 1 , wherein the antibody is a humanized antibody.
14. The composition according to claim 6 , wherein the composition comprises:
a) an antibody comprising a light chain comprising SEQ ID No. 49 and a heavy chain comprising SEQ ID No. 50; or
b) CD151-binding fragment of said antibody.
15. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to any one of claims 11 , 12 , and 13 .
16. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to claim 2 .
17. The method according to claim 15 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.
18. The method according to claim 16 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.
19. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 6 .
20. The method according to claim 19 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.
21. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 7 .
22. The method according to claim 21 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.
23. A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 8 .
24. The method according to claim 23 , wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer.